Feb 22,2022

Medtronic’s Q3 revenues miss as COVID-19 slows procedures

Medtronic (NYSE:MDT) shares rose this morning on third-quarter results that were mixed compared to the consensus forecast — with the company predicting a Q4 uptick. The Fridley, Minnesota-based medtech giant posted profits of $1.5 billion, or $1.10 per share, on sales of $7.8 billion for the three months ended Jan. 28, 2022, for a 16.5% bottom-line gain on a minor sales decline of 0.1%.

View Analyst & Ambassador Comments
Go to original news
Feb 22,2022

Tandem Diabetes Care Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2021 and financial guidance for the year ending December 31, 2022.

View Analyst & Ambassador Comments
Go to original news
Feb 23,2022

BD Appoints Shana Neal as Chief People Officer

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shana Neal has been appointed chief people officer, effective April 4, 2022.

View Analyst & Ambassador Comments
Go to original news
Feb 23,2022

Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year

Full Year 2021 revenue of $1.1 billion, up 21.5%, or 19.7% in constant currency 1 , compared to $904.4 million in the prior year.

View Analyst & Ambassador Comments
Go to original news
Feb 23,2022

embecta to Host Virtual Investor Event Ahead of Planned Spinoff from BD

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that embecta, the diabetes care business that is expected to spin off from BD on April 1, 2022, will host a virtual Investor Event on March 7, 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 24,2022

Global Continuous Glucose Monitoring Device Market (2022 to 2029) - Share, Size, Trends, Industry Analysis Report

The global continuous glucose monitoring device market size is expected to reach USD 14.78 billion by 2029 according to this new study.

View Analyst & Ambassador Comments
Go to original news
Feb 24,2022

BD to Present at the Cowen 42nd Annual Health Care Conference

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will virtually present at the Cowen 42nd Annual Health Care Conference via webcast.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 24,2022

Vida Health — Three Questions. Three Slides. Three Minutes

Chief Marketing Officer of Vida Health, Kevin Knight speaks to Benefit Sally on Vida Health

View Analyst & Ambassador Comments
Go to original news
Feb 25,2022

Insights on the Glucose Monitoring Devices Global Market to 2027 - Technological Advancements and Excessive Research & Development Presents Opportunities

The Global Glucose Monitoring Devices Market size was estimated at USD 5,291.78 million in 2020 and expected to reach USD 5,900.86 million in 2021, at a CAGR of 11.94% to reach USD 11,656.60 million by 2027.

View Analyst & Ambassador Comments
Go to original news
Feb 25,2022

Global Continuous Glucose Monitoring Systems Market (2021 to 2027) - by Component, Demographics, End-user and Region

The Global Continuous Glucose Monitoring Systems Market size was estimated at USD 3,969.03 million in 2020, is expected to reach USD 4,432.35 million in 2021, and is projected to grow at a CAGR of 12.03% to reach USD 8,794.97 million by 2027.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES